Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kyowa Kirin, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed diagnosis of MF or SS
* Stage IB, II-A, II-B, III, or IV;
Participants who have failed at least one prior course of systemic therapy (e.g., interferon, bexarotene, photopheresis, anti-neoplastic chemotherapy). Psoralen plus ultraviolet light therapy (PUVA) is not considered a systemic therapy.
You may not be if
Current evidence of large cell transformation;
Prior treatment with mogamulizumab;
History of allogeneic transplant.
Clareo Health | Mogamulizumab Q4week Dosing in Participants With R/R CTCL
